Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.

Autor: LoVecchio F; College of Health Solutions, Arizona State University, Phoenix, Arizona., McCarthy MW; Cornell University and New York Presbyterian Hospital, New York, New York., Ye X; AbbVie Inc., North Chicago, Illinois., Henry AD; Genesis Research, West One Forth Banks, Newcastle Upon Tyne, UK., Doan QV; Genesis Research, Hoboken, New Jersey., Lock JL; AbbVie Inc., North Chicago, Illinois., Riccobene T; AbbVie Inc., North Chicago, Illinois., Lyles RD; AbbVie Inc., North Chicago, Illinois. Electronic address: rosie.lyles@abbvie.com., Talan DA; Ronald Reagan UCLA Medical Center, University of California at Los Angeles, Los Angeles, California.
Jazyk: angličtina
Zdroj: The Journal of emergency medicine [J Emerg Med] 2024 Aug; Vol. 67 (2), pp. e217-e229. Date of Electronic Publication: 2024 Mar 12.
DOI: 10.1016/j.jemermed.2024.03.003
Abstrakt: Background: A pathway for the treatment of acute bacterial skin and skin structure infections (ABSSSI) with a single intravenous (IV) dose of dalbavancin was previously shown to reduce hospital admissions and shorten inpatient length of stay (LOS).
Objectives: To describe pathway implementation at the emergency department (ED) and evaluate cost-effectiveness of a single-dose dalbavancin administered to ED patients who would otherwise be hospitalized to receive usual care with multidose IV antibiotics.
Methods: The dalbavancin pathway was previously implemented at 11 U.S. EDs (doi:10.1111/acem.14258). Patients with ABSSSI, without an unstable comorbidity or infection complication requiring complex management, were treated with a single dose of dalbavancin. At the emergency physicians' discretion, patients were either discharged and received outpatient follow-up or were hospitalized for continued management. A decision analytic cost-effectiveness model was developed from the U.S. healthcare's perspective to evaluate costs associated with the dalbavancin pathway compared with inpatient usual care. Costs (2021 USD) were modeled over a 14-day horizon and included ED visits, drug costs, inpatient stay, and physician visits. One-way and probabilistic sensitivity analyses examined input parameter uncertainty.
Results: Driven largely by the per diem inpatient cost and LOS for usual care, the dalbavancin pathway was associated with savings of $5133.20 per patient and $1211.57 per hospitalization day avoided, compared with inpatient usual care. The results remained robust in sensitivity and scenario analyses.
Conclusion: The new single-dose dalbavancin ED pathway for ABSSSI treatment, which was previously implemented at 11 U.S. EDs, offers robust cost savings compared to inpatient usual care.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Frank LoVecchio was a consultant for AbbVie and has been paid for participating in speakers bureaus for AbbVie. Matthew W. McCarthy has no disclosures or conflict of interest. Xiaolan Ye, John L. Lock, Todd Riccobene, and Rosie D. Lyles are full-time employees of AbbVie and may own stocks/shares of the company. Alasdair D. Henry and Quan V. Doan are employees of Genesis Research and have received funding from AbbVie. David A. Talan was a consultant for AbbVie.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: